

Cancerology - Cancerology: real-world patient database in oncology & onco-hematology

Head :Geneviève Bonnelye, Health division

Last update : 10/29/2020 | Version : 1 | ID : 73432

General	
Identification	
Detailed name	Cancerology: real-world patient database in oncology & onco-hematology
Sign or acronym	Cancerology
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	French Cancerology database is conducted as part of the commitment of the MR-004 reference methodology which covers the data processing and delivered by the French Data Protection Authority (CNIL) with the authorization number n°2204473 v 0
General Aspects	
Medical area	Cancer research Hematology Rare diseases
Pathology (details)	Oncology (solid and non-solid tumours)
Health determinants	Addictions Genetic Geography Healthcare system and access to health care services Lifestyle and behavior Medicine Nutrition Pollution Social and psychosocial factors
Keywords	Oncology, solid tumour, non-solid tumour, liquid tumour, patient characteristics, treatment sequencing, haematology, clinical profile, biomarker, chemotherapy, targeted therapy, safety, comorbidities
Scientific investigator(s) (Contact)	
Name of the director	Geneviève

Surname	Bonnelye
Address	3 avenue Pierre Masse 75014 Paris
Phone	+33 1 40 92 47 58
Email	genevieve.bonnelye@kantarc.com
Unit	Health division
Organization	Kantar Health division
Collaborations	
Participation in projects, networks and consortia	No
Funding	
Funding status	Private
Details	Syndicated database funded by multiple client subscriptions
Governance of the database	
Sponsor(s) or organisation(s) responsible	Kantar Health division SAS
Organisation status	Private
Presence of scientific or steering committees	No
Additional contact	
Name of the contact	Hélène
Surname	Chalubert
Address	3 avenue Pierre Masse 75014 Paris
Phone	+33 1 40 92 24 33
Email	Helene.Chalubert@kantarc.com
Unit	Health division
Organization	Kantar Health division

Name of the contact	Cécile
Surname	Pacheco
Address	3 avenue Pierre Masse 75014 Paris
Phone	+33 7 50 12 72 80
Email	Cecile.PACHECO@kantar.com
Unit	Health division
Organization	Kantar Health division
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health care professionals A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Cancerology database uses a 2-stage clustered sampling process with: - firstly a screening phase to identify the sites and medical wards involved in the management of cancer patients - secondly an intensive phase to update the database via an extraction of patient-level data by participating physicians, directly from medical charts. 40-80 physicians are involved in the database update (per tumour and country) representing 100-400 case report forms (per tumour and country). Possibility for extra case report forms.
Database objective	
Main objective	To determine the epidemiology, patient & tumour characteristics, biomarkers, detailed treatment patterns, safety, and clinical outcomes across 25+ solid and non-solid tumours in France, Germany, Italy, Spain and the UK.

Inclusion criteria	Patients currently receiving active anti-tumour drug treatment.
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Pathology	C00-C97 - Malignant neoplasms
Gender	Male Woman
Geography area	International
Detail of the geography area	France, Germany, Italy, Spain, UK
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	1993
Date of last collection (YYYY or MM/YYYY)	2020
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	Please contact Kantar Health division directly.
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Declarative data Biological data
Clinical data (detail)	Medical registration
Details of collected clinical data	Patient characteristics, clinical profile, tumour

characteristics, safety, clinical outcomes

Declarative data (detail)	Paper self-questionnaire
Details of collected declarative data	Patient count
Biological data (detail)	Biomarkers
Presence of a biobank	No
Health parameters studied	Health event/morbidity Others

Procedures

Data collection method	Face-to-face self-administered questionnaire and case report forms
Quality procedure(s) used	ISO 20252
Participant monitoring	No
Followed pathology	
Links to administrative sources	No

Promotion and access

Promotion

Link to the document	E. Manna, K. Kikuchi , H. Chalubert , I. Amri, P. Medina. BRAF mutation testing and results among French patients with solid tumours. Poster to be presented at ESMO 2020.
Link to the document	Bassila L, Medina P, Chalubert H. Trends in anti-emetic drug use in hematology-oncology based on Cancerology data in France. Poster to be presented at ISPOR US 2020.
Link to the document	Klein AB, Wand H, Shire N, Chalubert H, Alessandrini ER, Descoins S, Medina P Treatment Patterns in Head and Neck Squamous Cell Cancer in France: ARTISTE Study of Cancerology Patient Charts. Value Health. 2017 Oct-Nov;20:A419
Link to the document	Medina P, Chalubert H, Pezic N, Wiegand J, Brihaye H, Spitzer M Epidemiologic burden of pulmonary metastasis in France. Value Health May 2019Volume 22, Supplement 2, Page S84.

Link to the document	Klein AB, Wand H, Shire N, Chalubert H, Alessandrini ER, Descoins S, Medina P Treatment patterns in non-small cell lung cancer in France: ARTISTE study of Cancerology patient charts. Value Health. 2017 Oct-Nov;20:A419
Link to the document	Colomer R, Hall P, Szkultecka-Debek M, Bondi RC, Flinois A, Auziere S, Le Cléac'h JY. Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC. Breast Cancer Res Treat. 2018 Feb;168(1):197-205. doi: 10.1007/s10549-017-4567-z.
Link to the document	Chabernaud H, Descoins S, Flinois A, Real-world studies in Onco-hematology: which parameter should be used to measure the efficacy of treatments, poster presented at ISPOR EU 2019.
Link to the document	Chabernaud H, Bonnelye G, Flinois A, French physician sensitivity to and consideration of the costs of cancer treatment, poster presented at ISPOR EU 2015.
Link to the document	Flinois A, Bonnelye G, Chabernaud H, Evolution of the number of patients treated for metastatic cancer between 2003 and 2013 in France, poster presented at ISPOR EU 2015.
Access	
Presence of document that lists variables and coding procedures	Yes
Terms of data access (charter for data provision, format of data, availability delay)	Please contact Kantar Health division directly.
Access to aggregated data	Access on specific project only
Access to individual data	No access